[EN] COMPOUNDS WHICH INHIBIT TRYPTASE ACTIVITY<br/>[FR] COMPOSES INHIBANT L'ACTIVITE DE LA TRYPTASE
申请人:ARRAY BIOPHARMA, INC.
公开号:WO1999024395A1
公开(公告)日:1999-05-20
(EN) The present invention is directed to compounds which are capable of inhibiting the activity of tryptase. Such compounds are useful in the treatment or prevention of inflammatory disease, particularly those disease states which are mediated by mast cell activation. Also encompassed by the invention are formulations comprising the noted compound, processes for preparing such compounds and methods for treating or preventing an inflammatory disease.(FR) La présente invention concerne des composés capables d'inhiber l'activité de la tryptase. Ces composés sont utiles dans le traitement ou la prévention de maladies inflammatoires, notamment des états pathologiques induits par l'activation des mastocytes. L'invention concerne également des formulations comprenant les composés précités, des processus permettant de les préparer et des procédés de traitement et de prévention d'une maladie inflammatoire.
275. Benzylamine analogues of chemotherapeutic diamidines
作者:Adrien Albert、John A. Mills、Richard Royer
DOI:10.1039/jr9470001452
日期:——
Derivatives of pentamidine designed to target the Leishmania lipophosphoglycan
作者:Kari L. Kramp、Kristin DeWitt、Jason W. Flora、David C. Muddiman、Kelli M. Slunt、Todd A. Houston
DOI:10.1016/j.tetlet.2004.11.112
日期:2005.1
The Leishmania lipophosphoglycan (LPG) is the most abundant cell surface glycoconjugate of a family of infectious protozoa. Pentamidine, a common drug used in the treatment of Leishmania infections, has been modified with boronic acids so that it might bind more selectively to the phosphodisaccharide repeating unit of the LPG. This could serve to target the drug to the protozoan surface and increase its efficacy in vivo. (C) 2004 Elsevier Ltd. All rights reserved.